JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results

• Main Authors: Krzysztof Szalus, Magdalena Trzeciak, Roman J. Nowicki
• Format: Article
• Language: English
• Published: MDPI AG 2020-11-01
• Series: Microorganisms
• Subjects: atopic dermatitis; JAK-STAT; abrocitinib; baricitinib; upadacitinib; tofacitinib
• Online Access: https://www.mdpi.com/2076-2607/8/11/1743

A common disease worldwide is known as atopic dermatitis (AD), named also as atopic eczema, which is a chronic recurrent complex inflammatory skin disorder. It affects 2–10% of the adult population and up to 20% of the pediatric population. The clinical AD picture appears in typically localized eczema and dry skin, and is dominated by a persistent pruritus followed by sleep disturbances. AD strongly impacts on the quality of life of AD patients and their families as well as on social and economic aspects. The pathogenesis of the disease is complex and consists of multiple interactions between immunological disturbances, skin barrier defect, and microbial dysbiosis with environmental influences. The treatment of AD reflects the pathogenetic disorders, starting from basic emollient therapy, and goes to topical anti-inflammatory regimens followed by phototherapy, systemic immunosuppressive drugs, and new biologic immunomodulators. This paper will thus summarize the novel collection of biological treatment JAK-STAT inhibitors dedicated to AD.